A new piece published by HCPLive, titled "Evaluating Treatment Selection in Psoriasis," takes up one of the most consequential decisions in daily dermatology practice: which therapy to prescribe, for which patient, and at what point in the disease course.

Psoriasis treatment selection has grown markedly more complex over the past decade. Clinicians now choose among tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, IL-23 inhibitors, IL-12/23 blockers, oral small molecules such as JAK inhibitors and deucravacitinib, and established agents including methotrexate and apremilast. Each class carries a distinct efficacy, safety, and convenience profile, and the HCPLive report frames the choice as a matter of matching those profiles to the individual patient rather than ranking drugs in isolation.

The coverage arrives as consensus guidance from professional bodies increasingly emphasizes a treat-to-target mindset. Absolute thresholds — PASI 90 or PASI 100 response, or clearance to clear/almost-clear status on the body surface area–weighted scales — have largely replaced looser endpoints such as PASI 50 when clinicians and patients discuss what success should look like. That shift, in turn, changes the calculus at initiation: a drug expected to deliver PASI 90 in a majority of trial participants sets a different expectation than one whose median response sits closer to PASI 75.

Patient-level factors remain central to the decision. Comorbidities weigh heavily — a patient with concomitant inflammatory bowel disease may steer away from certain IL-17 inhibitors, while concerns about weight gain or gastrointestinal intolerance can argue against oral agents. Patient preference on route and frequency of administration matters as well; an every-12-week maintenance dosing schedule is a different proposition from daily oral therapy or more frequent injections. Insurance design, step-therapy requirements, and prior authorization timelines shape the practical menu of options before efficacy data ever enter the conversation.

Safety monitoring obligations also divide the field. Traditional systemic agents require routine laboratory surveillance, while the newer biologics demand less monitoring but carry their own labeled warnings and screening considerations, including tuberculosis and hepatitis evaluation before initiation.

The full HCPLive report walks through how specialists weigh these variables when individualizing therapy, from the first-line decision in a treatment-naïve patient through switching and sequencing after an inadequate response.

As the therapeutic armamentarium continues to expand, the practical question for clinicians is shifting from whether effective options exist to how to sequence them rationally — a question the HCPLive coverage aims to help answer.